- Home
- SGC vs OABI Comparison
SGC vs OABI Comparison
Compare SGC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- OABI
- Stock Information
- Founded
- SGC 1920
- OABI 2012
- Country
- SGC United States
- OABI United States
- Employees
- SGC N/A
- OABI N/A
- Industry
- SGC Apparel
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- OABI Health Care
- Exchange
- SGC Nasdaq
- OABI Nasdaq
- Market Cap
- SGC 163.3M
- OABI 185.9M
- IPO Year
- SGC N/A
- OABI N/A
- Fundamental
- Price
- SGC $9.99
- OABI $1.41
- Analyst Decision
- SGC Strong Buy
- OABI Strong Buy
- Analyst Count
- SGC 3
- OABI 3
- Target Price
- SGC $17.00
- OABI $7.00
- AVG Volume (30 Days)
- SGC 48.1K
- OABI 923.1K
- Earning Date
- SGC 05-08-2025
- OABI 05-08-2025
- Dividend Yield
- SGC 5.62%
- OABI N/A
- EPS Growth
- SGC N/A
- OABI N/A
- EPS
- SGC 0.45
- OABI N/A
- Revenue
- SGC $563,931,000.00
- OABI $26,744,000.00
- Revenue This Year
- SGC $1.02
- OABI N/A
- Revenue Next Year
- SGC $3.98
- OABI $40.06
- P/E Ratio
- SGC $22.17
- OABI N/A
- Revenue Growth
- SGC 2.28
- OABI 27.07
- 52 Week Low
- SGC $9.11
- OABI $1.22
- 52 Week High
- SGC $21.80
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- SGC 46.88
- OABI 37.81
- Support Level
- SGC $9.69
- OABI $1.22
- Resistance Level
- SGC $9.96
- OABI $1.43
- Average True Range (ATR)
- SGC 0.32
- OABI 0.08
- MACD
- SGC 0.03
- OABI 0.02
- Stochastic Oscillator
- SGC 41.30
- OABI 36.59
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.